Entresto, Cosentyx, and Kisqali were Novartis AG’s three best-selling products in 2025, accounting for over ** percent of total pharmaceutical sales. The share of the company's top three drugs in each year increased constantly. Novartis, a Switzerland-based company, manufactures prescription medicines across cardiovascular, immunology, oncology, and neuroscience therapeutic areas.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Novartis. (February 3, 2026). Sales share of Novartis AG's three major drugs from 2021 to 2025 [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 30, 2026, from /statistics/1659665/novartis-ag-s-major-three-drugs-sales-share/
Novartis. "Sales share of Novartis AG's three major drugs from 2021 to 2025." Chart. February 3, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 30, 2026. /statistics/1659665/novartis-ag-s-major-three-drugs-sales-share/
Novartis. (2026). Sales share of Novartis AG's three major drugs from 2021 to 2025. ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 30, 2026. /statistics/1659665/novartis-ag-s-major-three-drugs-sales-share/
Novartis. "Sales Share of Novartis Ag's Three Major Drugs from 2021 to 2025." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 3 Feb 2026, /statistics/1659665/novartis-ag-s-major-three-drugs-sales-share/
Novartis, Sales share of Novartis AG's three major drugs from 2021 to 2025 ÌÇÐÄÆƽâ°æ, /statistics/1659665/novartis-ag-s-major-three-drugs-sales-share/ (last visited July 30, 2026)
Sales share of Novartis AG's three major drugs from 2021 to 2025 [Graph], Novartis, February 3, 2026. [Online]. Available: /statistics/1659665/novartis-ag-s-major-three-drugs-sales-share/
